Takeda Halts Phase II Studies For Key R&D Asset TAK-994 In Narcolepsy
‘Wave 1’ Drug Part Of Orexin Agonist Portfolio
The company stopped Phase II clinical trials for TAK-994 to assess a safety signal and determine next steps for the drug, which is viewed as a key product in Takeda’s push for blockbuster revenue growth.
You may also be interested in...
PRIME: EMA Says Yes To Only Three Of Twenty Hopefuls
The past few months have seen the European Medicines Agency award its much sought-after priority medicines designation to treatments for Hunter syndrome, bubble boy disease and narcolepsy.
Jazz Gets Second Indication For Xywav As First Therapy For Idiopathic Hypersomnia
Following last year’s approval in cataplexy for the Xyrem follow-on, Jazz could realize additional revenue of up to $500m annually with the first and only approval in IH, analysts say.
Takeda Highlights Rare Neurological Disorder Programs In Wave 1
Seeing significant unmet medical needs and insufficiently met needs in narcolepsy and rare types of epilepsy, Takeda has shifted its neuroscience focus.